Table 1.
Baseline Patient, Angiographic, and Procedural Characteristics According to Uric Acid Levels
| Variable | Overall (n=10 486) | Low uric acid level (n=3495) | Medium uric acid level (n=3497) | High uric acid level (n=3494) | P value |
|---|---|---|---|---|---|
| Age, y | 59 (51–65) | 60 (54–67) | 58 (51–65) | 56 (49–64) | <0.001 |
| Male, n (%) | 8094 (77.2) | 2151 (61.5) | 2827 (80.8) | 3116 (89.2) | <0.001 |
| Body mass index, kg/m2 | 25.9 (23.9–27.8) | 25.3 (23.2–27.4) | 25.8 (23.9–27.7) | 26.5 (24.5–28.4) | <0.001 |
| Current smoker, n (%) | 5990 (57.1) | 1624 (46.5) | 2070 (59.2) | 2296 (65.7) | <0.001 |
| Diabetes, n (%) | 4430 (42.2) | 1695 (48.5) | 1441 (41.2) | 1294 (37.0) | <0.001 |
| Hypertension, n (%) | 6755 (64.4) | 2185 (62.5) | 2210 (63.2) | 2360 (67.5) | <0.001 |
| Dyslipidemia, n (%) | 7068 (67.4) | 2283 (65.3) | 2337 (66.8) | 2448 (70.1) | <0.001 |
| Previous myocardial infarction, n (%) | 1965 (18.7) | 571 (16.3) | 679 (19.4) | 715 (20.5) | <0.001 |
| Previous PCI, n (%) | 2553 (24.3) | 816 (23.3) | 891 (25.5) | 846 (24.2) | 0.113 |
| Previous CABG, n (%) | 423 (4.0) | 115 (3.3) | 150 (4.3) | 158 (4.5) | 0.021 |
| Previous stroke, n (%) | 1120 (10.7) | 390 (11.2) | 371 (10.6) | 359 (10.3) | 0.482 |
| Peripheral vascular disease, n (%) | 282 (2.7) | 96 (2.7) | 100 (2.9) | 86 (2.5) | 0.570 |
| eGFR <60 mL/min per 1.73 m2, n (%) | 309 (3.1) | 56 (1.7) | 71 (2.1) | 182 (5.4) | <0.001 |
| COPD, n (%) | 241 (2.3) | 80 (2.3) | 78 (2.2) | 83 (2.4) | 0.920 |
| LVEF <50%, n (%) | 410 (4.0) | 118 (3.5) | 123 (3.6) | 169 (5.0) | 0.002 |
| Acute coronary syndrome, n (%) | 6272 (59.8) | 2149 (61.5) | 2056 (58.8) | 2067 (59.2) | 0.045 |
| Systolic blood pressure, mm Hg | 125 (120–140) | 130 (120–140) | 125 (120–140) | 122 (115–139) | <0.001 |
| Laboratory data | |||||
| Triglyceride, mmol/L | 1.53 (1.14–2.10) | 1.40 (1.05–1.89) | 1.51 (1.13–2.03) | 1.72 (1.28–2.37) | <0.001 |
| Total cholesterol, mmol/L | 4.05 (3.44–4.81) | 4.06 (3.46–4.81) | 4.01 (3.40–4.77) | 4.09 (3.46–4.84) | 0.026 |
| LDL‐C, mmol/L | 2.35 (1.86–3.01) | 2.35 (1.86–2.97) | 2.32 (1.83–3.00) | 2.38 (1.88–3.06) | 0.119 |
| HDL‐C, mmol/L | 0.99 (0.84–1.18) | 1.06 (0.89–1.26) | 1.00 (0.84–1.17) | 0.94 (0.80–1.10) | <0.001 |
| Hemoglobin A1c, % | 6.2 (5.8–7.0) | 6.3 (5.9–7.4) | 6.2 (5.8–6.9) | 6.1 (5.8–6.7) | <0.001 |
| Uric acid, mg/dL | 5.64 (4.78–6.58) | 4.40 (3.89–4.78) | 5.64 (5.36–5.91) | 7.04 (6.58–7.73) | <0.001 |
| Radial artery access, n (%) | 8853 (91.4) | 2957 (90.8) | 2948 (91.5) | 2948 (91.8) | 0.394 |
| 3‐vessel disease, n (%) | 4539 (43.3) | 1489 (42.6) | 1515 (43.3) | 1535 (43.9) | 0.608 |
| SYNTAX score | 10 (6–17) | 10 (6–17) | 10 (6–17) | 10 (6–17) | 0.731 |
| Type B2 or C lesion, n (%) | 8063 (76.9) | 2685 (76.8) | 2679 (76.6) | 2699 (77.2) | 0.813 |
| No. lesions treated ≥3, n (%) | 714 (6.8) | 239 (6.8) | 235 (6.7) | 240 (6.9) | 0.967 |
| No. stents ≥3, n (%) | 2327 (22.2) | 743 (21.3) | 776 (22.2) | 808 (23.1) | 0.172 |
| Use of EES/ZES, n (%) | 5477 (52.2) | 1818 (52.0) | 1841 (52.6) | 1818 (52.0) | 0.835 |
| Minimum stent diameter, mm | 2.75 (2.50–3.00) | 2.75 (2.50–3.00) | 2.75 (2.50–3.00) | 2.75 (2.50–3.00) | <0.001 |
| Total stent length, mm | 36 (23–55) | 33 (23–54) | 35 (23–55) | 37 (23–57) | 0.001 |
| Medications at discharge | |||||
| Aspirin, n (%) | 10 348 (98.7) | 3444 (98.5) | 3453 (98.7) | 3451 (98.8) | 0.658 |
| P2Y12 receptor inhibitor, n (%) | 10 326 (98.5) | 3438 (98.4) | 3443 (98.5) | 3445 (98.6) | 0.734 |
| β‐Blockers, n (%) | 9447 (90.1) | 3160 (90.4) | 3132 (89.6) | 3155 (90.3) | 0.433 |
| Statins, n (%) | 10 056 (95.9) | 3335 (95.4) | 3371 (96.4) | 3350 (95.9) | 0.121 |
| Calcium channel blockers, n (%) | 5138 (49.0) | 1764 (50.5) | 1691 (48.4) | 1683 (48.2) | 0.101 |
CABG indicates coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; EES, everolimus‐eluting stent; eGFR, estimated glomerular filtration rate; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; SYNTAX, synergy between percutaneous coronary intervention with TAXUS and cardiac surgery; and ZES, zotarolimus‐eluting stent.
Data were presented as median (interquartile range), mean±SD or frequencies (percentages).